A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00381082|
Recruitment Status : Completed
First Posted : September 27, 2006
Last Update Posted : December 12, 2006
To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups.
The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.
|Condition or disease||Intervention/treatment||Phase|
|Pediculosis||Drug: 1) MOOV Head Lice Treatment (Ego Pharmaceutical). Drug: Banlice Mousse Aerosol (Pfizer, Australia) Drug: 3) KP24 Medicated Foam (Nelson Laboratories)||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||152 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.|
|Study Start Date :||September 2004|
|Study Completion Date :||November 2004|
- Absence of live head lice one week after the last treatment for each product (ie at Day 14 for KP24 and Banlice and at Day 21 for MOOV Head Lice Treatment)
- Absence of live head lice one day after the first treatment of each product
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381082
|University of Queensland|
|Brisbane, Queensland, Australia, 4072|
|Principal Investigator:||Stephen Barker, PhD||The University of Queensland|